Cannabis News
Market-moving headlines, earnings, and regulatory shifts across the cannabis sector
Track the developments that move cannabis stocks — from quarterly earnings and M&A deals to state-level legalization votes and federal policy changes. Articles are tagged with relevant stock tickers so you can see which companies are affected and jump straight to their market data.
Idaho Medical Cannabis Initiative Advances to State Review for November Ballot
Natural Medical Alliance of Idaho submits county-verified petitions to state officials for final approval, potentially opening new market opportunity.
MSOS ETF Surges to Two-Year High on Cannabis Rescheduling Momentum
AdvisorShares Pure US Cannabis ETF reaches highest levels since 2022 as investors position ahead of potential DEA rescheduling decision.
DEA Backs Cannabis Schedule III Move at Administrative Hearing
Federal agency signals support for rescheduling with limited witness testimony as industry awaits regulatory shift that could reshape taxation and banking.
The Cannabist Company Surges on 3.3x Volume Spike at $0.03
CBSTF trades at 5.4M shares, over triple its 30-day average, as the multi-state operator gains 4.29% amid heightened investor interest.
TerrAscend Corp Sees 6.5x Volume Surge Amid Cannabis Rally
TSNDF trades over 2 million shares, 6.5x its 30-day average, as the multi-state operator attracts heightened investor attention.
Ayurcann Holdings Trades Near Zero as Cannabis LP Faces Crisis
AYURF shares hover at $0.00 with minimal trading volume, reflecting severe operational and financial challenges facing the licensed producer.
Weed Inc (BUDZ) Surges 9.8% on Volume as Penny Stock Eyes Recovery
Weed Inc shares jumped 9.8% to $0.03 on above-average trading volume, marking a significant move for the micro-cap cannabis operator.
Indiva Shares Plummet 10.1% to $0.02 on Heavy Trading Volume
NDVAF stock dropped to $0.02 with volume exceeding 510,000 shares as the micro-cap cannabis producer faces continued market pressures.
1933 Industries Surges 10.4% Despite Micro-Cap Challenges
TGIFF climbed to $0.01 on light volume, highlighting volatility in distressed cannabis micro-caps trading near penny stock territory.
TPCO Holding Stock Plummets 13% to $0.16 on Heavy Volume
The Parent Company's shares tumbled to new lows amid broader cannabis sector weakness and operational headwinds.
Cayman Islands Maps Cannabis Reform Path After Decriminalization Vote
Government commission outlines regulatory framework options following successful referendum, signaling Caribbean expansion for cannabis markets.
Cayman Islands Advances Cannabis Reform After Decriminalization Vote
Caribbean territory's Law Reform Commission releases framework options following voter approval, potentially opening new market opportunities for operators.
Teen Cannabis Study Links Usage to Doubled Mental Health Disorder Risk
Major longitudinal study of 463K teens shows cannabis use doubles risk of psychotic and bipolar disorders, adding regulatory pressure to industry expansion efforts.
Blueberries Medical Surges 19% as Penny Stock Attracts Volume
BBRRF climbed to $0.01 on elevated trading volume of 26,100 shares, representing significant momentum for the micro-cap international cannabis player.
Greater Cannabis Company Crashes 36% as Stock Hits Near 52-Week Low
GCAN shares plummeted to $0.12 amid low volume trading, extending the stock's dramatic 96.7% decline from its 52-week high of $3.60.
FinCanna Capital Surges 38% Despite Zero Price Point Anomaly
FNNZF experiences dramatic percentage gain while trading at zero price point, raising questions about OTC market mechanics and data reporting.
Memory Chip Giant Micron Eyes Major 2025 Breakthrough Amid AI Boom
Semiconductor manufacturer positions for potential milestone as artificial intelligence demand drives memory market recovery and investor optimism.
UK Medical Cannabis Patients Face Employment Barriers Despite Legal Status
Legal medical cannabis users in Britain struggle with workplace policies as employers lack clear frameworks for handling prescribed treatments.
DEA Rescheduling Hearing Reveals Industry's Regulatory Crossroads
Federal hearing exposes cannabis sector's regulatory uncertainty as stakeholders debate marijuana's classification future
DEA Rescheduling Hearing Exposes Cannabis Reform's Unfinished Business
Industry observers note key gaps in federal marijuana policy discussions as DEA weighs Schedule III move, highlighting regulatory uncertainty ahead.